Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors

  • He, Zhan-De (Department of Digestive Disease, XuYi Hospital of Traditional Chinese Medicine) ;
  • Huang, Xin-En (Department of Medical Oncology, Jiangsu Cancer Hospital) ;
  • Zhou, Jian-Nong (Department of Colorectal Cancer, Jiangsu Cancer Hospital)
  • Published : 2015.07.13


Background: To investigate the diagnostic and treatment methods for Chinese patients with gastrointestinal stromal tumor (GIST). Materials and Methods: From January 2004 to June 2014, patients diagnosed with primary GIST and treated by a single medical team in the Department of Digestive Disease of XuYi Hospital of Traditional Chinese Medicine were retrospectively recruited. Re-examination and follow-up was conducted regularly and abdominal enhanced CT, blood biochemistry and responses to surgery or imatinib were recorded. Results: A total of 15 patients were enrolled, including 9 male and 6 female patients, with an average age of 54 years (ranging from 32-81 years). The primary symptoms were abdominal uncomfortable in 5 patients, abdominal pain in 6 patients as well as nausea and vomiting in 4 patients. One patient was diagnosed with bowl obstruction at the first visit. All patients were treated with surgery, and tumor site was confirmed 1 esophagus, 6 stomach, 4 small bowel, and 4 colorectal and all patients were pathologically diagnosed with GIST. Immunochemical test positive for CD 117 was found 12 patients, and positive for CD 34 in7 patients. The median follow-up time was 24 months (range of 3-63). Three metastasis were confirmed 1.5, 2 and 2.6 years postoperatively. Three patients were treatment by imatinib postoperatively. Conclusions: Surgery remains the main treatment method for Chinese patients with GIST and imatinib could be feasible and safe for treating Chinese patients with GIST.


Gastrointestinal stromal tumor;imatinib mesylate;postoperative therapy


  1. Blay JY, Le Cesne A, Cassier PA, Ray-Coquard IL (2012). Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med, 13, 357-367.
  2. Bosman F T, Carneiro F, Hruban R H (2010). WHO classification of tumours of the digestive system 4th ed.: IARC, Lyon Press. 74-6.6(ed).
  3. Cassier PA, Ducimetie're F, Lurkin A, et al (2010). A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer, 103, 165-70.
  4. Corless CL, Feltcher JA, Heinrich MC (2004). Biology of gastrointestinal Stromal tumors. J Clin Oncol, 22, 3813-25.
  5. Dematteo RP, Ballman KV, Antonescu CR, et al (2009). American college of surgeons oncology group (ACOSOG) intergroup adjuvant GIST study team adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 373, 1097-104.
  6. Blanke CD, Demetri GD, von Mehren M, et al (2008). Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastastic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 26, 620-5.
  7. Blanke CD, Rankin C, Demetri GD, et al (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26, 626-32.
  8. Demetri GD, von Mehren M, Blanke CD, et al (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, 472-80.
  9. ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors (2012): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 23, 49-55.
  10. Fletcher CD, Berman JJ, Corless C, et al (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol, 10, 81-9.
  11. Hohenberger P, Eisenberg B (2010). Role of surgery combined with kinase inhibition in management of gastrointestinal Stromal tumor (GIST). Ann Surg Oncol, 17, 2585-600.
  12. Joensuu H, Eriksson M, Sundby Hall K, et al (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor a randomized trial 2012. JAMA, 307, 1265-72.
  13. Joensuu H, Hohenberger P, Corless CL (2013). Gastrointestinal stromal tumour. Lancet, 382, 973-83.
  14. Liegl-Atzwanger B, Fletcher JA, Flethcher CD (2010). Gastrointestinal stromal tumors. Virchows Arch, 456, 111-27.
  15. Miettinen M, Lasota J (2006). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 23, 70-83.
  16. Nilsson B, Sjolund K, Kindblom LG, et al (2007). Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer, 96, 1656-8.
  17. Perez EA, Livingstone AS, Franceschi D, et al (2006).Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg, 202, 623-9.
  18. Rutkowshi P, Debiec-Rychter M, Ruka W (2008). Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther, 12, 131-43.
  19. Rutkowski P, Gronchi A, Hohenberger P, et al (2013). Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol, 20, 2937-43.
  20. Wang C, Zheng B, Chen Y, et al (2013). Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs. Chin J Cancer Res, 25, 63-70.